Target Vessel Failure is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or cardiac death.

For the IDEAL -LM study, MACCE is defined as: all-cause death; stroke; myocardial infarction or ischemia driven target vessel revascularization.

(Composite of Target Vessel Revascularization and Target Vessel Inadequacy); Definite or Probable stent thrombosis (ARC criteria); Binary angiographic restenosis.

For the CELTIC BIRFUCATION Study Clinical and Angiographic composite is defined as: Death, Myocardial Infarction, CVA (cerebrovascular events), Target Vessel Failure

Heart disease due to discrete de novo native coronary artery lesions.

bifurcation and multi-vessel disease stenting. The SYNERGY Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic

Boston Scientific’s involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about

our products. Safety and performance of the SYNERGY Coronary Stent System has not been established for use in patients with STEMI, Left Main, chronic total occlusion,

in ACS patients (RCT 1:1)

in ACS patients (RCT 1:1);

OCT healing substudy at 3-months

A Prospective Registry

A Prospective Registry

Efficacy objective: compare procedure time required to cross CTO or abort procedure with CrossBoss first vs. antegrade wire escalation. Safety objective: compare frequency of procedural MACCE with upfront use of CrossBoss vs. guidewire escalation.

Principal Investigator: J. Aaron Grantham, MD

Principal Investigator: Simon Walsh, MD

Principal Investigator: David Foley, MD

Principal Investigator: Robert-Jan van Geuns, MD

Principal Investigator: J. Aaron Grantham, MD

Principal Investigator: Simon Walsh, MD

Principal Investigator: Robert-Jan van Geuns, MD

Principal Investigator: J. Aaron Grantham, MD

Principal Investigator: Olivier Varenne MD, PhD

Principal Investigator: Clemens von Birgelen, MD, PhD

1. Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators.

2. For the SYNTAX II study, MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization.

3. The SYNERGY Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions.

4. For the IDEAL -LM study, MACCE is defined as: all-cause death; stroke; myocardial infarction or ischemia driven target vessel revascularization.

5. Target Vessel Failure is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or cardiac death.

6. Target Vessel Failure is defined as any ischemia-driven revascularization of the target vessel. MI (Q-wave and non–Q-wave) related to the target vessel or cardiac death.